CNBC Healthy Returns

About

How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.

CNBC presents a one-day event at NYC’s Roosevelt Hotel that brings together top health care investors, CEOs and technologists to explore the innovations that will drive better outcomes, financially and clinically.

Every health care company seeks to scale the best technology and develop profitable ways to cover the massive cost of research and development, investors are looking for actionable intelligence on who’s breaking through, and patients are hungry for affordable and effective care. Healthy Returns is a convening of leaders who are improving patient outcomes, maximizing innovation, building great new companies and reinventing incumbents.

Led by CNBC’s anchors and reporters and with input from a world-class advisory board, Healthy Returns will hone in on groundbreaking ideas that will transform the health care industry, cutting through the noise and weeding out the "sales pitch."

Attendees should expect to walk away with smart strategies and actionable insights from people who are shaping the industry, including:

Investment ideas and intelligence from the biggest and best health care hedge funds, venture capitalists and portfolio managers.

Strategic perspective from top health care CEOs.

• An early, inside look at groundbreaking, transformative innovations.

• Unique networking opportunities to connect with leaders in multiple disciplines – investors, executives, entrepreneurs and innovators.

Who should attend:

Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.

Speakers

More speakers will be announced soon.

Tap or click a card to reveal more information:

Amy Abernethy
Amy Abernethy M.D., Ph.D, serves as chief medical officer, chief scientific officer and senior vice president, oncology of Flatiron Health.

READ MORE
Amy Abernethy M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Flatiron Health
Anthony Blau
Anthony Blau is Founder of All4Cure and Professor of Medicine/Hematology at the University of Washington

READ MORE
C. Anthony Blau, M.D.
Founder, All4Cure
Abbie Celniker
Abbie Celniker joined Third Rock in 2016 and prior to that, she served as president and CEO of Eleven Biotherapeutics.

READ MORE
Abbie Celniker, Ph.D.
Partner, Third Rock Ventures

Tony Coles
Dr. Coles is the chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company. He also serves as chairman and chief executive officer of TRATE Enterprises LLC.
READ MORE
Tony Coles, M.D.
Chairman and CEO, Yumanity Therapeutics
David Cordani
David Cordani became president and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company, doubling the size of the company in six years.
READ MORE
David Cordani
President and CEO, Cigna
Delos Cosgrove
Dr. Cosgrove is president and chief executive officer of Cleveland Clinic, presiding over an $8 billion health-care system.

READ MORE
Delos M. Cosgrove, M.D.
President and CEO, Cleveland Clinic
Alex Denner, PHD
Alex Denner is the founding partner and chief investment officer at Sarissa Capital Management LP. Previously, he served as a senior manager director at Icahn Capital.

READ MORE
Alex Denner, Ph.D.
Founding Partner and Chief Investment Officer, Sarissa Capital Management LP
Esther Dyson
Esther Dyson is chairman of EDventure Holdings. Her primary activity is investing in and nurturing start-ups, with a recent focus on health care, human capital and aerospace.

READ MORE
Esther Dyson
Chairman, EDventure Holdings
Andrew Farnum
Andrew Farnum is the Director of Program-Related Investments at the Bill & Melinda Gates Foundation, where he manages the foundation's $2 billion strategic investment program.

READ MORE
Andrew Farnum
Director of Program-Related Investments, Bill and Melinda Gates Foundation
Bill George
Bill George is an American businessman and academic. He is professor of Management Practice and a Henry B. Arthur Fellow of Ethics, at Harvard Business School.

READ MORE
Bill George
Senior Fellow, Harvard Business School and Former Chairman and CEO, Medtronic
Scott Gottlieb
Dr. Gottlieb is the 23rd commissioner of the Food and Drug Administration.

READ MORE
Scott Gottlieb, M.D.
Commissioner of Food and Drugs, U.S. FDA
Julie Grant
Julie Grant leads investments in biopharma and digital health companies at Canaan and is laser focused on identifying companies that will tangibly improve patient care.

READ MORE
Julie Grant
Partner, Canaan
Fred Hassan
Fred Hassan is a special limited partner and managing director with the private equity firm, Warburg Pincus and chairman of Caret Group.

READ MORE
Fred Hassan
Special Limited Partner, Warburg Pincus and Chairman, Caret Group
Jeff Jonas
Jeff Jonas is CEO of SAGE Therapeutics and has more than 20 years of experience in the pharmaceutical and healthcare industries

READ MORE
Jeff Jonas, M.D.
CEO, SAGE Therapeutics
Jeffrey Kahn
Jeffrey Kahn is the Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics.

READ MORE
Jeffrey Kahn, Ph.D., M.P.H.
Director, Johns Hopkins Berman Institute of Bioethics
Jessica Mega
Jessica L. Mega, M.D., M.P.H, is the chief medical officer at Verily Life Sciences.

READ MORE
Jessica L. Mega, M.D., M.P.H
Chief Medical Officer, Verily Life Sciences
Faisal Mushtaq
Faisal Mushtaq is the Chief Executive Officer of Truveris.

READ MORE
Faisal Mushtaq
CEO, Truveris
John Noseworthy
Dr. John H. Noseworthy is president and chief executive officer of Mayo Clinic.

READ MORE
John Noseworthy, M.D.
President and CEO, Mayo Clinic
Chris O'Connor
Chris O’Connor is a Partner at Perella Weinberg Partners and Co-Head of the firm’s U.S. Advisory Business.

READ MORE
Chris O'Connor
Partner, Perella Weinberg Partners
Kyu Rhee
Kyu Rhee is Chief Health Officer of IBM.

READ MORE
Kyu Rhee, M.D.
Chief Health Officer, IBM
John Noseworthy
Leonard S. Schleifer, M.D., Ph.D., is the founder, president and chief executive officer of Regeneron Pharmaceuticals.

READ MORE
Leonard S. Schleifer, M.D., Ph.D.
Founder, President and CEO, Regeneron Pharmaceuticals
Todd Sisitsky
Todd B. Sisitsky is the managing partner of TPG Capital, co-head of the firm’s global health care investing platform, and a member of the firm’s executive committee.

READ MORE
Todd B. Sisitsky
Managing Partner, TPG Capital
Craig Venter
J. Craig Venter, Ph.D., is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research.

READ MORE
Craig Venter, Ph.D.
Co-founder and Executive Chairman, Human Longevity
Agenda Wednesday, March 28th
8:00–9:00 am

Registration and Continental Breakfast

9:00-10:40 am

Welcoming Remarks

Tyler Mathisen, Co-Anchor, “Power Lunch,” CNBC

The Gatekeeper: Opening Conversation with FDA Commissioner Scott Gottlieb

When he took the lead at the FDA, Scott Gottlieb was seen as a pro-pharma choice. His legacy thus far, however, has been far more complicated. He’s taken on market inefficiencies, is approving generics at a record pace and trying to bring down drug prices. We’ll talk to him about what’s next at the FDA, including his vision for attacking the opioid crisis and his plans to balance public safety with faster drug approvals.
Scott Gottlieb, M.D., Commissioner of Food and Drugs, U.S. FDA
Interviewer: Meg Tirrell, Biotech and Pharma Reporter CNBC

The Investor Angle: What We’re Excited About Now

Leading investors give brief presentations on what they view as the most exciting and investable opportunities in health care for 2018 and beyond.
Venture Capital: Esther Dyson, Executive Founder, Way to Wellville; Board Member, 23 and Me and Open Humans Foundation
M&A: Christopher O'Connor, Partner, Perella Weinberg Partners
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street,", CNBC

Getting Personal: Why It Matters

Thirteen-year-old Paige Whorton lives her life with great gusto. “I like parasailing, exploring and ziplining — daredevil stuff,” she says with a giggle. But she developed debilitating, degenerative pain in her joints, and doctors couldn’t diagnose its cause. That’s where genetic testing and personalized medicine came in — and saved her life.
Paige Whorton
John Noseworthy, M.D., President and CEO, Mayo Clinic

Editing Ethically: Big Hopes And Big Fears About CRISPR

Few medical innovations have engendered as much excitement as CRISPR, but the gene-editing technology raises serious ethical questions: Will the power to edit our own DNA outpace our ability to decide as a society how far we want to go? In a global race for advancements, how do we balance the quest for innovation and better health against worries about “designer babies” and unleashing irreversible genetic changes?
Luke Dow, Ph.D., Assistant Professor of Biochemistry in Medicine, Weill Cornell Medicine
Jeffrey Kahn, Ph.D., Director, Johns Hopkins Berman Institute of Bioethics
Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC

10:40–11:10 am

Networking Break


11:10-12:30 pm

Innovation at Scale: Is Bigger Better...or Worse?

Many of the most innovative companies in the pharmaceutical industry today are smaller, more agile companies that focus on a limited number of technologies to drive innovation. More than ever, pharma giants are buying these upstart ventures to spur research and development. Is there an inverse relationship between company size and innovation?
Abbie Celniker, Ph.D., Partner, Third Rock Ventures
Fred Hassan Special Limited Partner, Warburg Pincus; Chairman, Caret Group; Former Chairman and CEO, Schering-Plough
Jeff Jonas, M.D., CEO, SAGE Therapeutics
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street," CNBC

Onstage Demonstration: Virtual Treatment for Real Pain

Presenter: David Sackman, Co-Founder and Chairman, appliedVR

WWAD: What Will Amazon Do?

The news that Jeff Bezos’ behemoth was partnering with J.P. Morgan Chase and Berkshire Hathaway to create a new health care venture sent health insurance stocks plummeting. It’s just a hint at Amazon’s potential disruptive, transformative role in health care. What’s next, and what’s their endgame?
Faisal Mushtaq, CEO, Truveris
Bill George, Senior Fellow, Harvard Business School; Former Chairman and CEO, Medtronic
Julie Grant, Partner, Canaan Partners; Board Member, Biden Cancer Initiative
Moderator: Christina Farr, Technology and Health Reporter, CNBC.com

12:30–1:45 pm

Lunch

Join us for lunch in the Terrace Room on the lobby level. Select tables will feature hosted discussions. Please see your programs and posted information for details.

1:45–2:55 pm

Sponsor Remarks

Neil De Crescenzo, President and CEO, Change Healthcare

Capitalizing Cures: Do Investors Inhibit Innovation?

It costs billions of dollars to develop revolutionary treatments and cures at scale, and often the only place to get that much funding is in the public markets. Investors, however, are focused on quarterly results and often have little patience with clinical trial setbacks and the years-long process of developing drugs. Is there a way to address this conflict?
Tony Coles, M.D., Chairman and CEO, Yumanity Therapeutics
Alex Denner, Ph.D., Founding Partner and CIO, Sarissa Capital Management
Leonard S. Schleifer, M.D., Ph.D., Founder, President and CEO, Regeneron Pharmaceuticals
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street," CNBC

The Investor Angle: What We’re Excited About Now

Leading investors give brief presentations on what they view as the most exciting and investable opportunities in health care for 2018 and beyond.
Private Equity: Todd B. Sisitsky, Managing Partner, TPG Capital
Private Investment: Andrew Farnum, Director of Program-Related Investments, Bill & Melinda Gates Foundation
Moderator: Tyler Mathisen, Co-Anchor, “Power Lunch,” CNBC

Onstage Demonstration: Alphabetizing Health Care

Presenter: Jessica L. Mega, M.D., M.P.H., Chief Medical Officer, Verily Life Sciences

2:55–3:25 pm

Networking Break


3:25-5:00 pm

Aligning Interests: New Models for Health Care Companies

With the urgent need to bring down the unsustainable costs of health care, many companies are pursuing toward M&A. Some health economists and insurance companies are also seeking a change from fee-for-service to an outcome-based model, offering incentives for successful and efficient treatments. Quality over quantity. Will these measures indeed provide better outcomes at lower costs?
David Cordani, President and CEO, Cigna
Delos ‘Toby’ Cosgrove, M.D., Former President and CEO, The Cleveland Clinic
Moderator: Bertha Coombs, Correspondent, CNBC

Getting Personal: Why It Matters

How one cancer researcher turned his own myeloma diagnosis into an opportunity, giving others the potential for greater control – and better outcomes – over their own care.
C. Anthony Blau, M.D., Professor of Medicine, Division of Hematology, Co-Director, Institute for Stem Cell and Regenerative Medicine; Director, Center for Cancer Innovation, University of Washington School of Medicine; Founder, All4Cure

Data vs. Disease: New Approaches

Cancer: Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer and SVP, Oncology, Flatiron Health
Opioids: Kyu Rhee, M.D., VP and Chief Health Officer, IBM
Interviewer: Meg Tirrell, Biotech and Pharma Reporter, CNBC

I Wanna Live Forever: A Conversation with Craig Venter

One of the leading scientists of our time, J. Craig Venter has been on the cutting edge of science for more than two decades. His institute is a leading organization dedicated to genomic research, and he’s the co-founder, executive chairman and CEO of Human Longevity. His institute is a leading research organization dedicated to genomic research, and he’s the co-founder, chairman and CEO of Human Longevity. We’ll find out what this visionary sees on the horizon in health care, science and medicine.
J. Craig Venter, Ph.D., Co-Founder, Executive Chairman and CEO, Human Longevity; Founder, Executive Chairman and CEO, J. Craig Venter Institute
Interviewer: Joe Kernen, Co-Anchor, “Squawk Box,” CNBC

5:00–6:00 pm

Cocktail Reception

Advisory Board

 

Tap or click a card to reveal more information:

Amy Abernethy
Amy Abernethy M.D., PhD, serves as chief medical officer, chief scientific officer and senior vice president, oncology of Flatiron Health.

READ MORE
Amy Abernethy M.D., PhD
Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Flatiron Health
Bruce Broussard
Bruce Broussard is President and CEO of Humana

READ MORE
Bruce Broussard
President and CEO, Humana
Tony Coles
Dr. Coles is the chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company. He also serves as chairman and chief executive officer of TRATE Enterprises LLC.
READ MORE
Tony Coles, M.D.
Chairman and CEO, Yumanity Therapeutics

David Cordani
David Cordani became president and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company, doubling the size of the company in six years.
READ MORE
David Cordani
President and CEO, Cigna
Tony Coles
Dr. Cosgrove is president and chief executive officer of Cleveland Clinic, presiding over an $8 billion health-care system.

READ MORE
Delos M. Cosgrove, M.D.
President and CEO, Cleveland Clinic
Ken Davis
Dr. Kenneth L. Davis, is president and chief executive officer of the Mount Sinai Health System in New York City, one of the nation's largest integrated health systems.

READ MORE
Kenneth Davis, M.D.
President and CEO, Mount Sinai Health System
Sue Desmond Hellmann
Dr. Sue Desmond-Hellmann is a physician, scientist and philanthropist and is currently the chief executive officer of the Bill & Melinda Gates Foundation.

READ MORE
Sue Desmond-Hellmann
CEO, Bill & Melinda Gates Foundation
Esther Dyson
Esther Dyson is chairman of EDventure Holdings. Her primary activity is investing in and nurturing start-ups, with a recent focus on health care, human capital and aerospace.

READ MORE
Esther Dyson
Chairman, EDventure Holdings
Bill George
Bill George is an American businessman and academic. He is professor of Management Practice and a Henry B. Arthur Fellow of Ethics at Harvard Business School.

READ MORE
Bill George
Senior Fellow, Harvard Business School and Former Chairman and CEO, Medtronic
Dr. Laurie Glimcher
Dr. Laurie H. Glimcher, president and chief executive officer of Dana-Farber Cancer Institute, is also chief executive officer of Dana-Farber/Partners CancerCare.

READ MORE
Laurie Glimcher, M.D.
President and CEO, Dana-Farber Cancer Institute
Fred Hassan
Fred Hassan is a special limited partner and managing director with the private equity firm, Warburg Pincus and chairman of Caret Group.

READ MORE
Fred Hassan
Special Limited Partner, Warburg Pincus and Chairman, Caret Group
Jessica Mega
Jessica L. Mega, M.D., M.P.H, is the chief medical officer at Verily Life Sciences.

READ MORE
Jessica L. Mega, M.D., M.P.H
Chief Medical Officer, Verily Life Sciences
John Noseworthy
Dr. John H. Noseworthy is president and chief executive officer of Mayo Clinic.

READ MORE
John Noseworthy, M.D.
President and CEO, Mayo Clinic
Sean Parker
Sean Parker is the founder and president of The Parker Foundation. He helped to establish the Stand Up 2 Cancer and Cancer Research Institute's (CRI) Immunology Dream Team in 2012.
READ MORE
Sean Parker
Founder and President, The Parker Foundation
Todd Sisitsky
Todd B. Sisitsky is the managing partner of TPG Capital, co-head of the firm’s global health care investing platform, and a member of the firm’s executive committee.

READ MORE
Todd B. Sisitsky
Managing Partner, TPG Capital
Eric Topol, M.D.
Eric Topol is the founder and director of the Scripps Translational Science Institute and professor of Molecular Medicine at the Scripps Research Institute.

READ MORE
Eric Topol, M.D.
Founder and Director, Scripps Translational Science Institute
Anne Wojcicki
Anne Wojcicki co-founded 23andMe in 2006 after a decade in health care investing focusing on biotechnology companies.

READ MORE
Anne Wojcicki
Co-Founder and CEO, 23andMe
Venue

The Roosevelt Hotel

The Roosevelt Hotel
45 E 45th Street
New York, NY 10017

There is a special CNBC room rate of $219 per night, plus tax. To reserve a room with this rate, please call the Roosevelt Hotel directly at 212-661-9600. Please note this special rate will be honored until February 27, 2018 or until the limited block has been filled.

Click here for hotel directions.

Sponsors
CONTACT

 

Are you looking for more information? Please contact the following: